Overcoming immunological tolerance to melanoma: Targeting CTLA-4

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue SUPPL. 1, 2010, Pages

  Hodi, F Stephen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Antibodies; Combination therapy; CTLA 4; Immunotherapy; Melanoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; PEPTIDE VACCINE; STEROID; TEMOZOLOMIDE; TICILIMUMAB;

ADRENAL DISEASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; COLITIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; ERYTHEMA; GENE TARGETING; HEPATITIS; HUMAN; HYPOPHYSIS DISEASE; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MAINTENANCE THERAPY; MELANOMA; MELANOMA B16; MULTIPLE CYCLE TREATMENT; NEPHRITIS; NONHUMAN; PANCREATITIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PRURITUS; SINGLE DRUG DOSE; T LYMPHOCYTE; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; UVEITIS;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, CD; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MELANOMA;

EID: 77950839518     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01271.x     Document Type: Article

References (38)

1. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-10.
2. Mihm MC, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996, 74:43-7.
3. Ribas A. Anti-CTLA4 antibody clinical trials in Melanoma. Update Cancer Ther 2007, 2:133-39.
4. Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007, 13:5238-42.
5. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006, 90:297-339.
6. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3:611-18.
7. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-65.
8. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-13.
9. Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002, 32:366-73.
10. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM. Reversal of the TCR stop signal by CTLA-4. Science 2006, 313:1972-5.
11. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-8.
12. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-7.
13. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-6.
14. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-66.
15. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001, 194:481-9.
16. Korman A, Yellin M, Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 2005, 6:582-91.
17. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003, 100:4712-17.
18. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003, 100:8372-77.
19. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005, 23:741-50.
20. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23:6043-53.
21. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005, 175:7746-54.
22. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005, 12:1005-16.
23. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005, 23:8968-77.
24. Weber JS, Targan S, Scotland R, Snively J, Garcia M, Yellin M. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol 2006, 24:Abstract 2510.
25. Weber JS, Hersh EM, Yellin M, Nichol GM, Urba W, Powderly JD. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. J Clin Oncol 2007, 25:Abstract 8523.
26. Ribas A, Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. J Clin Oncol 2007, 25:Abstract 3000.
27. Ribas A, Hauschild A, Kefford R, Gomez-Navarro J, Pavlov D, Marshall MA. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008, 26:Abstract LBA9011.
28. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007, 110:2614-27.
29. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006, 106:2437-44.
30. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006, 24:2283-9.
31. Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF, Pavlov D. Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206. J Clin Oncol 2007, 25:Abstract 3038.
32. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005, 28:593-8.
33. Hodi FS, Hoos A, Ibrahim R, Chin K, Pehamberger H, Harmankaya K. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol 2008, 26:Abstract 3008.
34. Weber JS, Berman D, Siegel J, Minor D, Amin A, Thompson JA. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol 2008, 26:Abstract 9010.
35. O'Day SJ, Ibrahim R, DePril V, Maio M, Chiarion-Sileni V, Gajewski TF. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J Clin Oncol 2008, 26:Abstract 9021.
36. Wolchok JD, Ibrahim R, DePril V, Maio M, Queirolo P, Harmankaya K. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment. J Clin Oncol 2008, 26:Abstract 3020.
37. Hamid O, Chin K, Li J, Neyns B, Linette G, Negrier S. Dose effect of ipilimumab in patients with advanced melanoma: results from a phase II, randomized, dose-ranging study. J Clin Oncol 2008, 26:Abstract 9025.
38. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008, 105:3005-10.